AstraZeneca PLC (AZN)

28.96
NYSE : Health Care
Prev Close 28.96
Day Low/High 0.00 / 0.00
52 Wk Low/High 25.55 / 35.60
Avg Volume 4.93M
Exchange NYSE
Shares Outstanding 2.53B
Market Cap 73.73B
EPS 1.40
P/E Ratio 13.06
Div & Yield 0.90 (3.10%)

Latest News

One of Wall Street's Hottest Biotech Stocks Tanks, Is Now the Time to Pounce?

One of Wall Street's Hottest Biotech Stocks Tanks, Is Now the Time to Pounce?

One of the hottest biotech stocks of the last month is selling off.

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Teva Shares Are Taking a Beating and Dragging Down the Generic Drugmakers

Teva said weak U.S. markets and the ongoing political turmoil in Venezuela weighed on the company's second quarter performance.

Acalabrutinib Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Mantle Cell Lymphoma

Acalabrutinib Granted Breakthrough Therapy Designation By US FDA For The Treatment Of Patients With Mantle Cell Lymphoma

AstraZeneca and its hematology research and development center of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib for...

Pfizer Investors Keep Eyes on Pipeline as Viagra, Lyrica Approach Patent Cliff

Pfizer Investors Keep Eyes on Pipeline as Viagra, Lyrica Approach Patent Cliff

A glimpse of what to expect during Tuesday's pre-market.

These Stocks Are Ready to Reverse Course

These Stocks Are Ready to Reverse Course

This week's bullish and bearish reversal patterns.

Clovis Sell-Off May Be Overdone

Clovis Sell-Off May Be Overdone

Clovis Oncology, Intercept Pharmaceuticals and Editas Medicine were among the biotech premarket movers on July 31.

AstraZeneca Shares Just Fell Sharply, So Here Is Your Next Move

AstraZeneca Shares Just Fell Sharply, So Here Is Your Next Move

Big volume is hitting AstraZeneca and a breakout trade could trigger soon.

European Benchmarks Mixed as Investors Weigh Corporate Earnings and Economic Data

European Benchmarks Mixed as Investors Weigh Corporate Earnings and Economic Data

Higher inflation and, in some parts, solid corporate earnings were both factors on Monday.

Charter Says No to Sprint - 5 Things You Must Know Before the Market Opens

Charter Says No to Sprint - 5 Things You Must Know Before the Market Opens

U.S. stock futures rise Monday following a record closing high for the Dow Jones Industrial Average to end last week.

IMFINZI™ (durvalumab) Granted Breakthrough Therapy Designation By US FDA For Patients With Locally Advanced Unresectable Non-Small Cell Lung Cancer

IMFINZI™ (durvalumab) Granted Breakthrough Therapy Designation By US FDA For Patients With Locally Advanced Unresectable Non-Small Cell Lung Cancer

AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for IMFINZI™ (durvalumab), an...

AstraZeneca Gets Breakthrough Designation For Imfinzi Following Pacific Trial

AstraZeneca Gets Breakthrough Designation For Imfinzi Following Pacific Trial

AstraZeneca's Imfinzi gets reprieve after MYSTIC failure

With Cancer Rival's Immuno-oncology Flop, Bristol-Myers Looks Less Enticing for Suitors Too

With Cancer Rival's Immuno-oncology Flop, Bristol-Myers Looks Less Enticing for Suitors Too

The results from a clinical trial of AstraZeneca's lung cancer treatment increase uncertainty about Bristol-Myers' immuno-oncology franchise, according to BMO analyst Alex Arfaei.

AstraZeneca Takeover Chatter Bubbles Up Again After Massive Drug Trial Disappointment

AstraZeneca Takeover Chatter Bubbles Up Again After Massive Drug Trial Disappointment

The British pharma company suffers a setback with a lung-cancer drug it touted as a defense against a Pfizer takeover bid three years ago, and could be back in play.

AstraZeneca Cancer Drug Failure Doesn't Bode Well For Bristol Myers

AstraZeneca Cancer Drug Failure Doesn't Bode Well For Bristol Myers

Shares lost more than 16% in London trading

Nasdaq Tumbles as Tech Takes a Turn Lower

Nasdaq Tumbles as Tech Takes a Turn Lower

The Nasdaq tumbles and the S&P 500 slides. The Dow rises slightly.

Amazon, AstraZeneca Are Explosive Stocks -- AZN, VZ, TWTR, CMCSA, AMZN, LUV

Amazon, AstraZeneca Are Explosive Stocks -- AZN, VZ, TWTR, CMCSA, AMZN, LUV

But not all stocks were helping to push the market higher.

European Benchmarks Sink Despite Solid Corporate Earnings

European Benchmarks Sink Despite Solid Corporate Earnings

Losses at several major index constituents sank markets Thursday.

AstraZeneca Shares Sink on Lackluster Mystic Drug Results

AstraZeneca Shares Sink on Lackluster Mystic Drug Results

AstraZeneca shares are tanking.

Wall Street Trades at Records as Facebook Rallies

Wall Street Trades at Records as Facebook Rallies

Stocks are higher.

Facebook, Twitter, Procter & Gamble, AstraZeneca: Hot Stocks to Watch

Facebook, Twitter, Procter & Gamble, AstraZeneca: Hot Stocks to Watch

These stocks were moving big before the market opened.

Alexion Spikes on Q2 Earnings Blowout Providing Positive Signs for Rest of Sector -Biotech Movers

Alexion Spikes on Q2 Earnings Blowout Providing Positive Signs for Rest of Sector -Biotech Movers

Alexion Pharmaceuticals, United Therapeutics and Gilead Sciences were among the biotech stock movers in premarket trading on July 27.

Stock Futures Power Higher on Earnings Beat From Facebook

Stock Futures Power Higher on Earnings Beat From Facebook

Stock futures are higher.

Facebook and PayPal Just Made Everyone Do a Double Take -- Watch 'Five Before the Bell'

Facebook and PayPal Just Made Everyone Do a Double Take -- Watch 'Five Before the Bell'

Facebook blows everyone away, again.

TAGRISSO® (osimertinib) Significantly Improves Progression-Free Survival In The Phase III FLAURA Trial For Lung Cancer

TAGRISSO® (osimertinib) Significantly Improves Progression-Free Survival In The Phase III FLAURA Trial For Lung Cancer

AstraZeneca today announced that the Phase III FLAURA trial showed a statistically-significant and clinically-meaningful progression-free survival (PFS) benefit with TAGRISSO ® (osimertinib) compared to current...

AstraZeneca's Lung Cancer Treatment Fails Trial; Q2 Earnings Top Estimates

AstraZeneca's Lung Cancer Treatment Fails Trial; Q2 Earnings Top Estimates

AstraZeneca calls MYSTIC results "disappointing".

European Stocks Set to Drift Lower Ahead of Active Week For Corporate Earnings

European Stocks Set to Drift Lower Ahead of Active Week For Corporate Earnings

Global equity rally takes a breather.

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

U.S. Economy Is Probably Limping Along Because of Frustrating Consumers: Week Ahead

Wall Street's first glimpse at the second quarter.